Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements 2023-07-28 15:27
Henlius Forecasts Profit in 1H 2023 2023-07-03 18:59
Henlius Forecasts Profit in 1H 2023 2023-07-03 17:49
Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged 2023-04-17 07:45
Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues 2023-04-01 00:06
EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab) 2023-03-24 08:00
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02 2023-02-15 16:49
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC 2023-01-17 19:42
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US 2023-01-07 17:29
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US 2022-11-30 08:00
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC 2022-11-01 21:32
ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world 2022-09-28 21:00
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma 2022-08-18 21:35
Henlius HANQUYOU Received TGA Approval in Australia 2022-07-26 18:03
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies 2022-06-28 21:50
ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022 2022-06-06 21:00
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA 2022-04-11 22:07
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer 2022-04-07 22:21
Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG 2022-03-25 21:24
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma 2022-03-17 08:00
1 2 3